Repligen (RGEN) Tops Q2 EPS by 20c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $179.26 +0.56%
Financial Fact:
Product revenue: 24.68M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Product revenue: 24.68M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.91, $0.20 better than the analyst estimate of $0.71. Revenue for the quarter came in at $207.6 million versus the consensus estimate of $189.6 million.
GUIDANCE:
Repligen sees FY2022 EPS of $3.13-$3.20, versus the consensus of $3.09. Repligen sees FY2022 revenue of $790-810 million, versus the consensus of $789 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
